Stock Ratings / Health Care / PNTG / earnings

TDOC (56) USPH (64) INNV (57) OMDA (56) ⌘ Pro Terminal →

The Pennant Group Inc. (PNTG) Next Earnings Date & Expected ±6.7% Move

$42.48 +0.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

The Pennant Group Inc. (PNTG) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $1.48B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PNTG)Realized 20D OHLCV Swing Band: ±6.7%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±6.7% Swing Band

±$2.85 Expected Swing

MODEL EARNINGS SETUP GAUGE

PNTG Quantitative Pre-Earnings Setup: 56/100

Trailing EPS: $0.85 • YoY Revenue Growth: 36.3%

Model Bullish Setup (56/100)Model Risk Weight (44/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$947.7M	$29.6M	$36.3M	52%
FY 2024	2024-12-31	$695.2M	$22.6M	$30.3M	52%
FY 2023	2023-12-31	$544.9M	$13.4M	$33.1M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PNTG)

✓Walkthrough of PNTG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PNTG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +35.63%⚡ TESTING RESISTANCE

2026-10-30O $42.78H $43.06L $41.35C $42.48VOL 367.8K

RES: $42.78SUP: $40.23SMA50: $39.96SMA200: $35.44

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PNTG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PNTG Butterfly Map → + Track PNTG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

36.5%/yr Implied 5Y Growth

vs. +36.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PNTG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PNTG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PNTG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PNTG)

Health Care Rank #263 of 1016 ⚔️ TDOC vs PNTG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PNTG vs. TDOC, USPH, INNV, OMDA)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, The Pennant Group Inc. (PNTG) ranks #263 by composite RQD confidence (56/100, grade D+) and #305 by equity capitalization ($1.48B). Within this direct 5-issuer industry benchmark cohort, USPH leads on earnings valuation at 32.6x trailing P/E, while USPH leads on capital efficiency and profitability with 11.5% ROIC and 19.2% gross margin. USPH currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with PNTG at 56/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PNTG ACTIVE The Pennant Group Inc.	D+	56/100	50.2x	—	11.0%	+0.76%	$1.48B	Benchmark Subject
TDOC Teladoc Health Inc.	D+	56/100	—	—	-17.0%	+26.89%	$1.59B	/tdoc-vs-pntg →
USPH U.S. Physical Therapy Inc.	C	64/100	32.6x	19.2%	11.5%	+1.47%	$1.29B	/usph-vs-pntg →
INNV InnovAge Holding Corp.	D+	57/100	—	18.0%	-10.2%	+1.54%	$1.26B	/innv-vs-pntg →
OMDA Omada Health Inc.	D+	56/100	—	65.7%	-15.7%	+2.45%	$1.20B	/omda-vs-pntg →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001766400

In its most recent audited fiscal period (FY2025, filed 2025-12-31), The Pennant Group Inc. (PNTG) reported GAAP revenue of $947.7M (+36.3% vs. FY2024 revenue of $695.2M , and +73.9% cumulative change since FY2023) , GAAP net income of $29.6M, operating cash flow of $48.3M, and free cash flow of $36.3M (+19.6% YoY). On the balance sheet, PNTG closed FY2025 with $968.2M in total assets against $0 in total debt (Altman Z-Score: 2.81, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$947.7M	$29.6M	$48.3M	$36.3M	$968.2M	—
FY2024 (FY)	2024-12-31	$695.2M	$22.6M	$39.3M	$30.3M	$679.5M	—
FY2023 (FY)	2023-12-31	$544.9M	$13.4M	$33.1M	$33.1M	—	—

3. PNTG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PNTG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, The Pennant Group Inc. (NASDAQ: PNTG) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $42.48 (+0.76% 1D, market cap $1.48B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, PNTG ranks #263 in composite RQD confidence.

How does PNTG compare to TDOC and USPH in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), PNTG carries a Roarable D+ (56/100 RQD), trailing P/E of 50.2x, gross margin of —, and ROIC of 11.0%. By comparison, TDOC (Teladoc Health Inc.) holds a D+ grade (56/100 RQD, P/E N/A, ROIC -17.0%, cap $1.59B) and USPH (U.S. Physical Therapy Inc.) posts a C grade (64/100 RQD, P/E 32.6x, ROIC 11.5%, cap $1.29B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PNTG?

Per PNTG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001766400), The Pennant Group Inc. generated $947.7M in revenue (+36.3% YoY), $29.6M in net income, and $36.3M in free cash flow against $968.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PNTG trading relative to its 50-day, 200-day, and 52-week technical levels?

PNTG last traded at $42.48 (+0.76% on volume of 369,293 shares), positioning the stock +6.31% above its 50-day simple moving average ($39.96) and +19.86% above its 200-day simple moving average ($35.44). Across its 52-week range of $22.26 to $43.41, PNTG sits at the 95.6% percentile with a 14-day RSI of 53.6 (NEUTRAL RANGE) and an implied next-earnings move of ±6.7% ($39.63 to $45.33).